Pulmonary NECs Market Poised for Steady Growth Through 2036 as DLL3-Targeted Therapies Challenge Chemotherapy Standard | Thelansis

Thelansis Knowledge Partners LLP today announced the publication of its latest report, "Pulmonary Neuroendocrine Carcinomas (NECs) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2026 to 2036," providing a comprehensive, data-driven view of one of oncology's most aggressive and historically underserved disease areas across the 8MM (US, Germany, France, Italy, Spain, UK, Japan, and China).

Request a free sample of Thelansis' Pulmonary Neuroendocrine Carcinomas (NECs) Market Outlook and Forecast Report to secure the complete 2026-2036 forecast, exclusive KOL insights, and competitive pipeline data across the 8 Major Markets: https://thelansis.com/reports/neuroendocrine-carcinoma-nec-market-outlook-forecast-2026-to-2036/

Executive Summary
• What are Pulmonary NECs? Pulmonary neuroendocrine carcinomas span small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) high-grade, rapidly proliferating tumors that behave aggressively and are frequently diagnosed at advanced or metastatic stage.
• A disproportionate disease burden: among all neuroendocrine carcinomas, the lung is the single most common primary site, accounting for the largest share of NEC diagnoses globally, ahead of stomach, pancreas, rectumm, and esophagus.
• Market in expansion mode: the broader neuroendocrine carcinoma treatment space is estimated at roughly USD 2.3-2.8 billion in 2026 and is projected to approach USD 4-7 billion by the early-to-mid 2030s, growing at a CAGR in the high single digits, with pulmonary NEC recognized as one of the fastest-growing indication segments.
• A biomarker is rewriting the playbook: Delta-like ligand 3 (DLL3), once an obscure Notch pathway protein, has emerged as a validated therapeutic target shared across SCLC, LCNEC, and extrapulmonary NEC opening the door to a new generation of bispecific and cell-directed therapies.
• China's growing weight: with an expanding oncology infrastructure, rising diagnostic capacity, and an increasingly active domestic biotech pipeline, China is fast becoming a central pillar of Asia-Pacific's growth story in this space.

Thelansis' report translates these dynamics into country-level epidemiological forecasts, indication-wise revenue modeling, and pipeline-readiness scoring designed to help biopharma strategy, market access, and BD teams act on this shifting landscape.

Key Emerging Players
The treatment paradigm for pulmonary NECs has long been anchored around cytotoxic chemotherapy - but a wave of DLL3-directed and other biomarker-guided assets is now advancing through the clinic:
• Amgen - IMDELLTRA (tarlatamab), a DLL3-targeting bispecific T-cell engager approved for relapsed extensive-stage SCLC, has shown encouraging responses in case reports of DLL3-positive LCNEC and is now being evaluated head-to-head against standard chemotherapy in pretreated pulmonary and gastroenteropancreatic NEC through an ongoing intergroup trial.
• Boehringer Ingelheim / Oxford BioTherapeutics - obrixtamig (BI 764532), a DLL3-targeted T-cell engager in active clinical development.
• Merck & Daiichi Sankyo - gocatamig (MK-6070), a DLL3-directed bispecific candidate.
• Zai Lab / MediLink Therapeutics - ZL-1310, a DLL3-targeted antibody-drug conjugate with direct relevance to the China market opportunity.
• Phanes Therapeutics - peluntamig (PT217), a dual DLL3/CD47-targeting bispecific that has received FDA Orphan Drug and Fast Track designations for neuroendocrine carcinoma indications.
• Legend Biotech / Novartis - LB2102, a DLL3-directed cell therapy candidate in early development.
• Abdera Therapeutics - ABD147, exploring a DLL3-targeted radiopharmaceutical approach.
The report benchmarks each candidate's mechanism, trial stage, and commercial readiness against the evolving competitive set.

Request a sample report for an in-depth analysis of key emerging players, pipeline staging, and mechanisms of action in Pulmonary Neuroendocrine Carcinomas (NECs): https://thelansis.com/reports/neuroendocrine-carcinoma-nec-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=nec_mo

Key Current Therapies / Standard of Care
• First-line backbone: platinum-based chemotherapy (cisplatin or carboplatin) combined with etoposide remains the default first-line regimen for pulmonary NEC, largely extrapolated from SCLC protocols.
• Response durability remains a challenge: initial response rates can be high, but relapse tends to occur quickly, with median overall survival generally ranging between 8 and 15 months depending on primary site and stage at diagnosis.
• Chemoimmunotherapy is gaining ground: combination regimens incorporating checkpoint inhibitors are increasingly used in practice, drawing on the immunotherapy paradigm established in SCLC.
• Surgery for early-stage disease: definitive local therapy remains an option for early-stage LCNEC, though a recent large-cohort molecular study found broadly comparable survival outcomes across chemotherapy, chemoimmunotherapy, and immunotherapy regimens - underscoring the absence of a clearly superior standard.
• No dedicated approval yet: outside of SCLC, no therapy currently carries an approval specific to LCNEC or pulmonary NEC, leaving a meaningful portion of patients treated off established, indication-specific evidence.

Key Market Drivers / Trends
• Molecular subtyping is redefining LCNEC: recent integrated genomic and transcriptomic analysis of nearly 600 patients has identified distinct NSCLC-like (KEAP1, KRAS, STK11-mutated) and SCLC-like (RB1, TP53-mutated) subtypes, with roughly 80% of tumors aligning with an SCLC-like transcriptional profile - a distinction expected to guide future treatment selection.
• DLL3 as a pan-NEC target: DLL3 expression spans SCLC, LCNEC, extrapulmonary NEC, and neuroendocrine prostate cancer, positioning a single biomarker-driven drug class to potentially address multiple high-grade neuroendocrine tumor types at once.
• Regulatory tailwinds: Orphan Drug and Fast Track designations awarded to emerging DLL3-class assets are compressing development timelines and signaling regulatory appetite for innovation in this underserved area.
• Diagnostic and imaging advances: improved molecular pathology and imaging are enabling earlier and more accurate identification of high-grade neuroendocrine lung tumors, expanding the diagnosed and treatable patient pool.
• Asia-Pacific momentum, China in focus: Asia-Pacific is consistently flagged as the fastest-growing region across neuroendocrine tumor and carcinoma treatment market analyses, with China's expanding cancer-care infrastructure and an increasingly active domestic biotech pipeline (including DLL3-targeted programs) reinforcing its role as a strategic growth market.
• Radiopharmaceutical capacity build-out: expanding isotope supply chains, particularly for Lutetium-177, are easing prior bottlenecks and supporting broader momentum across the wider neuroendocrine tumor treatment ecosystem.

Translate these macro drivers into a competitive advantage. Request the Thelansis Pulmonary Neuroendocrine Carcinomas (NECs) sample report to unlock granular pipeline analysis, deal tracking, and market forecasts: https://thelansis.com/reports/neuroendocrine-carcinoma-nec-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=nec_mo

Key Unmet Need & KOL Expectations
• Beyond platinum chemotherapy: key opinion leaders continue to emphasize the urgent need for therapeutic strategies beyond platinum-based regimens, given how frequently responses are short-lived and relapse occurs early.
• Trial representation gaps: pulmonary NEC and LCNEC have historically been underrepresented in pivotal oncology trials, leaving optimal treatment sequencing and duration of therapy poorly defined.
• Calls for indication-specific trial design: there is growing consensus around the need for LCNEC- and NEC-specific trial inclusion criteria and biomarker-driven enrollment (such as DLL3 status), rather than folding these patients into broader NSCLC or SCLC study baskets.
• CNS involvement remains understudied: management of brain metastases in pulmonary NEC patients receiving novel bispecific therapies is flagged as an area requiring dedicated investigation, following early case-level evidence of activity in patients with untreated CNS disease.
The report incorporates KOL commentary and unmet-need mapping to help stakeholders align pipeline positioning with where clinical demand is most acute.

Commercial Opportunity
• Rare-disease incentives at play: Orphan Drug and Fast Track designations translate into extended market exclusivity, pricing flexibility, and expedited regulatory pathways - an incentive structure that continues to draw biotech and pharma investment into this space.
• First-mover advantage in DLL3-directed therapy: Companies with validated DLL3-targeted assets and companion diagnostic capability are well positioned to capture disproportionate share as the standard of care pivots away from chemotherapy alone.
• China as a strategic access point: Active domestic pipeline development, illustrated by programs already underway with China-based biotechs, points to meaningful partnership, licensing, and market-entry opportunities within the country.
• Actionable, decision-ready intelligence: The Thelansis report delivers indication-level and country-level (8MM including China) revenue modeling, epidemiology-based patient forecasting through 2036, pipeline maturity scoring, and market entry strategy insights - built for BD, market access, and portfolio strategy teams evaluating where to play in this fast-evolving landscape.

Access the complete Pulmonary Neuroendocrine Carcinomas (NECs) market outlook and forecast report to explore the evolving market and future commercial opportunities: https://thelansis.com/reports/neuroendocrine-carcinoma-nec-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pressrelease&utm_campaign=nec_mo

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.